Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-18-030649

Chief Executive Officer acquired 21,500 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kulkarni Samarth · Chief Executive Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2018-12-07 Exercise or conversion : show line 1 in the form +21,500 $1.81 $38,915 167,290 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2018-12-07 Exercise or conversion : show line 2 in the form Stock Options (Right to Buy) −21,500 243,058 D
Loading xslF345X03/doc4.xml…